Exelixis Pharmaceuticals Inc., Imperial Cancer Research Technology, Indiana University Foundation, Yale University deal

Exelixis, a functional genomics company, signed an exclusive license

Read the full 99 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE